The Principles of Clinical Cytogenetics - Extra Materials - Springer

414 Rizwan Naeem
116. Dèohner, H., Stilgenbauer, S., Fischer, K., Bentz, M., and Lichter, P. (1997) Cytogenetic and molecular cytogenetic
analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of
patients and point to loci of candidate genes. Leukemia 11(Suppl. 2), S19–S24.
117. Oscier, D.G., Thompsett, A., Zhu, D., and Stevenson, F.K. (1997) Differential rates of somatic hypermutation in V(H)
genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 89, 4153–4160.
118. Dèohner, H., Stilgenbauer, S., James, M.R., et al. (1997) 11q deletions identify a new subset of B-cell chronic lymphocytic
leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89, 2516–2522.
119. Juliusson G., Oscier D.G., Fitchett, M., et al. (1990) Prognostic subgroups in B-cell chronic lymphocytic leukemia
defined by specific chromosomal abnormalities. N. Engl. J. Med. 323(11), 720–724.
120. Matutes, E., Oscier, D., Garcia-Marco, J., et al. (1996) Trisomy 12 defines a group of CLL with atypical morphology:
correlation between cytogenetic, clinical and laboratory features in 544 patients. Br. J. Haematol. 92, 382–388.
121. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G., and Stevenson, F.K. (1999) Unmutated Ig V(H) genes are associated
with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848–1854.
122. Berger, F., Felman, P., Thieblemont, C., et al. (2000) Non-MALT marginal zone B-cell lymphomas: a description of
clinical presentation and outcome in 124 patients. Blood 95, 1950–1956.
123. Mollejo, M., Menárguez, J., Lloret, E., et al. (1995) Splenic marginal zone lymphoma: a distinctive type of low-grade
B-cell lymphoma. A clinicopathological study of 13 cases. Am. J. Surg. Pathol. 19, 1146–1157.
124. Isaacson, P.G., Matutes, E., Burke, M., and Catovsky, D. (1994) The histopathology of splenic lymphoma with villous
lymphocytes. Blood 84, 3828–3834.
125. Matutes, E., Morilla, R., Owusu-Ankomah, K., Houlihan, A., and Catovsky, D. (1994) The immunophenotype of splenic
lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B cell disorders. Blood
83, 1558–1562.
126. Zhu, D., Oscier, D.G., and Stevenson, F.K. (1995) Splenic lymphoma with villous lymphocytes involves B-cells with
extensively mutated Ig heavy chain variable region genes. Blood 85, 1603–1607.
127. Mateo, M., Mollejo, M., Villuendas, R., et al. (1999) 7q31–32 allelic loss is a frequent finding in splenic marginal zone
lymphoma. Am. J. Path. 154, 1583–1589.
128. Corcoran, M.M., Mould, S.J., Orchard, J.A., et al. (1999) Dysregulation of cyclin dependent kinase 6 expression in
splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 18(46), 6271–6277.
129. Gruszka-Westwood, A.M., Matutes, E., Coignet, L.J., Wotherspoon, A., and Catovsky, D. (1999) The incidence of
trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br. J. Haematol. 104, 600–604.
130. Mulligan, S.P., Matutes, E., Dearden, C., and Catovsky, D. (1991) Splenic lymphoma with villous lymphocytes: natural
history and response to therapy in 50 cases. Br. J. Haematol. 78, 206–209.
131. Grogan, T.M. and Spier, C.M. (2001) The B cell immunoproliferative disorders including multiple myeloma and
anyloidosis. In Neoplastic Hematopathology. Vol. 2. (Knowles, D.M., ed.), Lippincott Williams and Wilkins,
Philadelphia.
132. Barlogie, B., Epstein, J., Selvanayagam, P., and Alexanian, R. (1989) Plasma cell myeloma—new biological insights
and advances in therapy. Blood 73, 865–879.
133. Dewald, G.W., Kyle, R.A., Hicks, G.A., and Greipp, P.R. (1985) The clinical significance of cytogenetic studies in 100
patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66, 380–390.
134. Durie, B.G. (1992) Cellular and molecular genetic features of myeloma and related disorders. Hematol. Oncol. Clin.
North Am. 6, 463–477.
135. Sawyer, J.R., Waldron, J.A., Jagnnath, S., and Barlogie, B. (1995) Cytogenetic findings in 200 patients with multiple
myeloma. Cancer Genet. Cytogenet. 82, 41–49.
136. Lai, J.L., Zandecki, M., Mary, J.Y., et al. (1995) Improved cytogenetics in multiple myeloma: a study of 151 patients
including 117 patients at diagnosis. Blood 85, 2490–2497.
137. Konigsberg, R., Zojer, N., Ackermann, J., et al. (2000) Predictive role of interphase cytogenetics for survival of patients
with multiple myeloma. J. Clin. Oncol. 18, 804–812.
138. Chesi, M., Bergsagel, P.L., Brents, L.A., Smith, C.M., Gerhard, D.S., and Kuehl, W.M. (1996). Dysregulation of cyclin
D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674–681.
139. Vasef, M.A., Medeiros, L.J., Yospur, L.S., Sun, N.C., Mccourty, A., and Brynes, R.K. (1997) Cyclin D1 protein in
mutiple myeloma and plasmacytoma: An immunohistochemical study using fixed, paraffin-bembedded tissue sections.
Mod. Pathol. 10, 927–932.
140. Mahmoud, M.S., Huang, N., Nobuyoshi, M., Lisukov, I.A., Tanaka, H., and Kawano, M.M. (1996) Altered expression
of Pax-5 gene in human myeloma cells. Blood 87, 4311–4315.
141. Dalton, W.S., Grogan, T.M., Meltzer, P.S., et al. (1989) Drug-resistance in multiple myeloma and non-Hodgkin’s
lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin.
Oncol. 7, 415–424.
142. Salmon, S.E. and Cassady, J.R. (1988) Plasma cell neoplasms. In Cancer, Principles and Practice of Oncology (DeVita,
V.T., Hellman, S., and Rosenberg, S., eds.), Lippincott, Philadelphia.